Capillary electrophoresis of urinary normal and modified nucleosides of cancer patients.

This paper gives a capillary electrophoretic method for the separation of 15 urinary normal and modified nucleosides from cancer patients in less than 40 min. A 500 mm x 50 microns uncoated capillary column (437.5 mm to window) was used. The effects of the voltage and the sodium dodecyl sulfate (SDS) concentration in the buffer on the separation were studied. With reproducibilities of migration times better than 1.2% (R.S.D.) and determined concentrations better than 5-25%, depending on the concentrations of nucleosides in the urine, the analytical characteristics of the method were good. Using this developed method, the concentrations of 13 normal and modified nucleosides, extracted on a phenyl boronic acid affinity chromatography column, in 25 urines from patients of 14 kinds of cancer were determined. The levels (nmol/mumol creatinine) of modified nucleosides in urines from cancer patients were increased as compared with those in normal urines.

[1]  C. Speicher,et al.  Elevated nucleoside excretion by patients with nasopharyngeal carcinoma: Preliminary diagnostic/prognostic evaluations , 1982, Cancer.

[2]  J. Mrochek,et al.  Urinary excretion by cancer patients of the nucleosides N-dimethylguanosine, 1-methylinosine, and pseudouridine. , 1973, Journal of the National Cancer Institute.

[3]  G. Björk,et al.  Tumor markers in mammary carcinoma. An evaluation of carcinoembryonic antigen, placental alkaline phosphatase, pseudouridine and CA-50. , 1987, Acta oncologica.

[4]  K. Schram,et al.  Isolation and identification of urinary nucleosides. Applications of high-performance liquid chromatographic methods to the synthesis of 5'-deoxyxanthosine and the simultaneous determination of 5,6-dihydrouridine and pseudouridine. , 1990, Journal of chromatography.

[5]  H. Widmer,et al.  Hologram-Based Thermooptical Absorbance Detection in Capillary Electrophoresis: Separation of Nucleosides and Nucleotides , 1995 .

[6]  C. C. Marvel,et al.  Altered RNA turnover in carcinogenesis , 1994, Molecular and chemical neuropathology.

[7]  E. Borek.  Toward a universal tumour marker. , 1984, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[8]  T. Samuelsson,et al.  Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil. , 1991, Nucleic acids research.

[9]  C. Gehrke,et al.  Tumor markers derived from nucleic acid components. , 1983, Cancer detection and prevention.

[10]  K. Schram,et al.  Urinary excretion of modified nucleosides as biological marker of RNA turnover in patients with cancer and AIDS. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[11]  D. Ettinger,et al.  Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. , 1982, European journal of cancer & clinical oncology.

[12]  G. Nass.  Modified Nucleosides and Cancer , 2011, Recent Results in Cancer Research/Fortschritte der Krebsforschung/Progrès dans les recherches sur Ie cancer.

[13]  G Sander,et al.  Ribonucleic acid turnover in man:RNA catabolites in urine as measure for the metabolism of each of the three major species of RNA. , 1986, Clinical science.

[14]  J. Langridge,et al.  Gas chromatography/mass spectrometric analysis of urinary nucleosides in cancer patients; potential of modified nucleosides as tumour markers. , 1993, Rapid communications in mass spectrometry : RCM.

[15]  H. Topp,et al.  5,6-Dihydrouridine: a marker ribonucleoside for determining whole body degradation rates of transfer RNA in man and rats. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[16]  C. Gehrke,et al.  The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer , 1975, Cancer.

[17]  Guowang Xu,et al.  Analysis of normal and modified nucleosides in urine by capillary electrophoresisa) , 1997 .

[18]  M. Mizugaki,et al.  An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides , 1993, Cancer.

[19]  G. Björk,et al.  Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. , 1995, Acta oncologica.

[20]  K. Kuo,et al.  Patterns of urinary excretion of modified nucleosides. , 1979, Cancer research.

[21]  D. Ettinger,et al.  Biological markers and small cell carcinoma of the lung. A clinical evaluation of urinary ribonucleosides , 1982, Cancer.

[22]  G. Björk,et al.  Tumor markers in bronchogenic carcinoma. An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudouridine. , 1983, Acta radiologica. Oncology.

[23]  H. Liebich,et al.  Quantitation of urinary nucleosides by high-performance liquid chromatography. , 1997, Journal of chromatography. A.

[24]  A. Niveleau,et al.  Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies. , 1992, Cancer letters.

[25]  A. Held,et al.  Interrelation between whole-body turnover rates of RNA and protein. , 1990, European journal of clinical nutrition.

[26]  K. Kuo,et al.  tRNA breakdown products as markers for cancer , 1979, Cancer.

[27]  M. Grever,et al.  Urinary nucleosides in leukemia: laboratory and clinical applications. , 1986, Critical reviews in clinical laboratory sciences.

[28]  C. Heierli,et al.  [Serum creatinine determination without protein precipitation]. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[29]  K. Kuo,et al.  Ribonucleoside analysis by reversed-phase high-performance liquid chromatography. , 1989, Journal of chromatography.